Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of PTHrP and PTH to Treat Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 45 - 75 year old Caucasian, Hispanic or Asian women~* one year post-menopausal if older than 50 years~* three years post-menopausal if between the ages of 45 - 50 years~* body mass index less than or equal to 30~* T-scores on screening Dual X-Ray Absorbiometry (DXA) scan between - 2.0 to - 4.5 of lumbar spine or hip~* have at lease two spinal vertebrae evaluable by DXA analysis~Exclusion Criteria:~* bisphosphonate therapy within the last two years~* estrogen replacement hormones or SERMS within last one year~* no more than one week of PTHrP, PTH, or an analog of PTH within the last year~* an atraumatic bone fracture within the last 6 months~* significant or active diseases of any organ system~* history of malignancy~* anemia with a hematocrit less than 34%~* significant drug or alcohol abuse~* having received any investigational drug within the last 90 days~* taking any medication that may interfere with skeletal metabolism, such as phenobarbital, dilantin, glucocorticoids, and hydrochlorathiazide~* abnormal screening labs including serum Ca greater than 10.5 g/dl, 25 hydroxy vitamin D less than 20 ng/ml or PTH greater than 65 pg/ml~* African-Americans for this particular study - although future studies are planned

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PTHrP 400 mcg/day (Type: EXPERIMENTAL): Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
- PTHrP 600 mcg/day (Type: EXPERIMENTAL): Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
- PTH 20 mcg/day (Type: ACTIVE_COMPARATOR): Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).